INVO Bioscience Faces Delisting Concerns, Restates Financials
Ticker: IVF · Form: 8-K · Filed: Sep 20, 2024 · CIK: 1417926
| Field | Detail |
|---|---|
| Company | Invo Bioscience, INC. (IVF) |
| Form Type | 8-K |
| Filed Date | Sep 20, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, financial-restatement, listing-standards
TL;DR
INVO Bioscience might get delisted and can't trust its old financials.
AI Summary
INVO Bioscience, Inc. filed an 8-K on September 20, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company also disclosed a non-reliance on previously issued financial statements or related audit reports. The filing indicates potential issues with the company's continued listing on an exchange.
Why It Matters
This filing signals significant financial distress and potential loss of exchange trading for INVO Bioscience, impacting investor confidence and liquidity.
Risk Assessment
Risk Level: high — The company is facing potential delisting and has declared non-reliance on previous financial statements, indicating severe financial and reporting issues.
Key Players & Entities
- INVO Bioscience, Inc. (company) — Registrant
- September 18, 2024 (date) — Earliest event reported
- September 20, 2024 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
- 001-39701 (identifier) — Commission File Number
- 20-4036208 (identifier) — IRS Employer Identification No.
- 5582 Broadcast Court Sarasota, Florida (address) — Business address
FAQ
What specific listing rule or standard has INVO Bioscience, Inc. failed to satisfy?
The filing states a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify which rule or standard has been violated in the provided text.
What is the reason for INVO Bioscience, Inc.'s non-reliance on previously issued financial statements?
The filing indicates a 'Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review' but does not detail the specific reasons for this non-reliance in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 18, 2024.
What is the Commission File Number for INVO Bioscience, Inc.?
The Commission File Number for INVO Bioscience, Inc. is 001-39701.
In which state was INVO Bioscience, Inc. incorporated?
INVO Bioscience, Inc. was incorporated in Nevada.
Filing Stats: 1,110 words · 4 min read · ~4 pages · Grade level 15.2 · Accepted 2024-09-20 16:05:10
Key Financial Figures
- $0.0001 — ction 12(b) of the Act: Common Stock, $0.0001 par value INVO The Nasdaq Stock Mar
- $1.00 — ment to maintain a minimum bid price of $1.00 per share for continued listing under N
Filing Documents
- form8-k.htm (8-K) — 43KB
- 0001493152-24-037589.txt ( ) — 214KB
- invo-20240918.xsd (EX-101.SCH) — 3KB
- invo-20240918_lab.xml (EX-101.LAB) — 33KB
- invo-20240918_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 20, 2024 INVO BIOSCIENCE, INC. By: /s/ Steven Shum Steven Shum Chief Executive Officer